Aisa Pharma

Executive Summary

Aisa Pharma is a private, clinical-stage biopharmaceutical company pioneering the repurposing and optimization of calcium channel blockers to address rare, serious diseases with high unmet medical need. The company's lead asset, AISA-021, is an oral dual-channel calcium blocker being developed for Raynaud's phenomenon in patients with systemic sclerosis (scleroderma). By targeting both L- and T-type calcium channels, AISA-021 aims to provide superior vasodilation and symptom relief compared to existing therapies like nifedipine, which often cause tolerability issues. The company has leveraged the known safety profile of calcium channel blockers to accelerate development, positioning it for a potentially efficient path to approval. Aisa Pharma is headquartered in Boston with operations in California and Australia, and is backed by private investors. Given the repurposing strategy and validated mechanism, Aisa Pharma faces lower preclinical risk but still must demonstrate clinical differentiation in a pivotal trial. The company is likely advancing AISA-021 through Phase 2 testing, with a focus on enrolling patients with scleroderma-related Raynaud's, a condition with no FDA-approved therapies. Key upcoming milestones include Phase 2 topline data and potential regulatory interactions. While competition exists from generic calcium blockers and other investigational agents, successful proof-of-concept could unlock significant value and support expansion into additional orphan indications. The company's private status limits public visibility, but progress in the clinic and strategic partnerships could catalyze the next phase of growth.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 Topline Data for AISA-021 in Systemic Sclerosis-Raynaud's60% success
• Q4 2026IND Submission for a New Indication (e.g., Digital Ulcers)50% success
• Q3 2026Strategic Partnership or Licensing Deal for AISA-02140% success